Merck partners with global health coalition to develop affordable Ebola vaccine

Core Viewpoint - Merck and the Coalition for Epidemic Preparedness Innovations have announced a partnership to develop an updated version of Merck's Ebola vaccine, with a funding commitment of $30 million aimed at improving public health responses to the Ebola virus [1] Group 1 - The partnership focuses on enhancing the existing Ebola vaccine to better address the needs of populations at risk [1] - The $30 million program is intended to support research and development efforts in vaccine technology [1] - This collaboration highlights the importance of public-private partnerships in addressing global health challenges [1]